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ABSTRACT
Background. Rigorous data are sparse concerning the optimal
route of administration and dosing strategy for iron therapy
with or without concomitant erythropoiesis-stimulating agent
(ESA) therapy for the management of iron deficiency anaemia
in patients with non-dialysis dependent chronic kidney disease
(ND-CKD).
Methods. FIND-CKD was a 56-week, open-label, multicentre,
prospective, randomized three-arm study (NCT00994318) of
626 patients with ND-CKD and iron deficiency anaemia ran-
domized to (i) intravenous (IV) ferric carboxymaltose (FCM)
at an initial dose of 1000 mg iron with subsequent dosing as
necessary to target a serum ferritin level of 400–600 µg/L (ii)
IV FCM at an initial dose of 200 mg with subsequent dosing
as necessary to target serum ferritin 100–200 µg/L or (iii) oral
ferrous sulphate 200 mg iron/day. The primary end point was
time to initiation of other anaemia management (ESA
therapy, iron therapy other than study drug or blood transfu-
sion) or a haemoglobin (Hb) trigger (two consecutive Hb
values <10 g/dL without an increase of ≥0.5 g/dL).
Results. The background, rationale and study design of the
trial are presented here. The study has been completed and
results are expected in late 2013.
Discussion. FIND-CKD was the longest randomized trial of
IV iron therapy to date. Its findings will address several unan-
swered questions regarding iron therapy to treat iron
deficiency anaemia in patients with ND-CKD. It was also the
first randomized trial to utilize both a high and low serum fer-
ritin target range to adjust IV iron dosing, and the first not to
employ Hb response as its primary end point.
Keywords: anaemia, ferric carboxymaltose, FIND-CKD,
intravenous iron, iron deficiency, non-dialysis CKD
BACKGROUND TO THE FERINJECT®
ASSESSMENT IN PATIENTS WITH IRON
DEFICIENCY ANAEMIA AND NON-DIALYSIS
DEPENDENT CHRONIC KIDNEY DISEASE
STUDY
Iron deficiency anaemia: a clinical challenge
Chronic kidney disease (CKD) affects >10% of adults in
developed countries [1–3], and the number is increasing as
populations age and contributory diseases such as diabetes and
hypertension become more common [1]. Only a small pro-
portion require dialysis [2, 3]. For patients with non-dialysis
CKD (ND-CKD), management focuses on interventions to
ameliorate further loss of kidney function, treating the multiple
co-morbidities and managing cardiovascular risk.
Anaemia is a frequent complication of CKD. Prevalence
estimates vary widely according to the definition which is
applied, but a large U.S. survey observed haemoglobin (Hb)
levels <12 g/dL in more than one in four with relatively mild
ND-CKD (Stages 1–2), increasing to more than half of those
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deficiency, iron deficiency is an important cause of anaemia in
ND-CKD, arising from multiple factors directly or indirectly
related to renal dysfunction [5]. Inflammation is also common
and is associated with increased hepcidin levels, which lead to
impaired absorption of iron from the gastrointestinal tract and
retention of iron in the reticuloendothelial system [6]. Both
absolute and functional iron deficiency limit erythropoiesis and
are the main cause of hyporesponsiveness to erythropoiesis-sti-
mulating agents (ESAs) [7–9]. In addition, iron is critical for
many other cellular functions, such as energy metabolism,
muscle performance and immune function [10, 11].
THE CURRENT EVIDENCE BASE
Anaemia management has centred on the use of ESA and iron
therapy for the last two decades. However, following safety
concerns associated with high-dose ESA therapy and aggres-
sive Hb targets in three large clinical trials in ND-CKD
patients (CREATE [12], CHOIR [13, 14] and TREAT [15]) the
appropriate management of anaemia has been questioned and
interest in the use of iron therapy has heightened. The latest
anaemia guideline from the Kidney Disease Improving Global
Outcomes (KDIGO) initiative recommends that iron therapy
should be used to correct iron deficiency before initiating ESA
therapy [16]. It also recommends use of iron therapy if an in-
crease in Hb is desired without starting ESA therapy or a de-
crease in ESA dose is desired.
The effectiveness of intravenous (IV) iron therapy in cor-
recting anaemia and replenishing iron stores has been demon-
strated in ND-CKD populations [17–21]. However, only one
randomized trial has compared the effectiveness of IV versus
oral iron therapy exclusively in ND-CKD patients not receiv-
ing concomitant ESA therapy [22] (Table 1). Limited data
from another three randomized studies were derived from
ESA-free subpopulation analyses in which the decision
whether to initiate ESA therapy was investigator driven [17–19].
In these three subpopulation analyses, 53.2% [17], 29.7% [18]
and 59.5% [19] of subjects had an Hb increase of 1 g/dL or
more with IV iron therapy alone. Moreover, treatment with IV
ferric carboxymaltose (FCM) alone achieved a greater increase
in Hb compared with oral iron and a comparable increase in
Hb to that observed with oral iron in combination with ESA
therapy [17]. This was coupled with significantly greater in-
creases in mean serum ferritin and transferrin saturation
(TSAT) levels in FCM-treated subjects versus those random-
ized to oral iron. In the only trial to have excluded ESA-treated
patients, IV ferric gluconate produced a more rapid Hb in-
crease compared with oral iron, although the final increase in
Hb was similar with either treatment. Notably, all four trials
had short-term follow-up, lasting only a maximum of 6 weeks
[17–19, 22], which is insufficient to draw any conclusions re-
garding longer term safety, and all four trials employed only
Hb response as their primary end point. The limited evidence
base relating to IV iron therapy without concomitant ESA in
patients with ND-CKD has obliged expert groups to extrap-
olate conclusions from the scientific evidence in dialysis
patients to the ND-CKD setting when developing anaemia
management guidelines [5, 16, 23, 24].
Although IV iron has been shown to replete iron stores
more effectively than oral iron in patients with ND-CKD
[17, 25, 26], a potential effect of iron repletion on outcomes
other than Hb level is largely unexplored in the ND-CKD
population. There is a growing awareness from trials in
patients with chronic heart failure, with and without con-
comitant ND-CKD, that the benefits of IV iron therapy in
iron-deficient individuals are not restricted to improved
erythropoiesis. The large, randomized FAIR-HF trial recently
demonstrated that IV iron therapy significantly improved
symptoms, quality of life and functional capacity versus
placebo even in non-anaemic patients with iron deficiency
[27]. Additionally, this study suggested that the correction of
iron deficiency with IV iron might improve renal function in
ND-CKD patients with chronic heart failure [27, 28].
Table 1. IV iron therapy versus oral iron in anaemic ND-CKD patients without concomitant ESA therapy in randomized, multicentre studies
Study N IV iron therapy Oral iron therapy Follow-up
(weeks)
Primary end point





111a FCM: single dose of 1000 mg iron (with
up to 2 additional 500 mg iron doses)
Ferrous sulphate: 65 mg
iron three times a day





145b Ferumoxytol: 2 doses of 510 mg iron Ferrous fumarate: 100
mg iron twice a day









47c Iron sucrose: 1000 mg iron in 2 or 5
doses
Ferrous sulphate: 65 mg
iron three times a day





75 Ferric gluconate: 4 doses of 250 mg iron Ferrous sulphate: 65 mg
iron three times a day







FCM, ferric carboxymaltose; Hb, haemoglobin; IV, intravenous; n/a, not available; n.s., not significant; SD, standard deviation.
aSubpopulation analysis: 111/255 patients did not receive ESA therapy.
bSubpopulation analysis: 145/304 did not receive ESA therapy.
cSubpopulation analysis: 47/161 did not receive ESA therapy.
dNo significant change versus baseline.
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USE OF IV IRON IN NON-DIALYSIS CKD
There is currently no widely accepted consensus on whether
IV or oral iron should be used as first-line therapy to replete
iron stores and treat iron deficiency anaemia in patients with
ND-CKD. The recent KDIGO Anemia Guideline, therefore,
proposes a 1- to 3-month trial of oral iron therapy in ND-CKD
and IV iron in patients receiving dialysis [16]. The recent
European Renal Best Practice position statement recommends a
minimum 3-month trial of oral iron unless there is gastrointes-
tinal intolerance, oral iron is ineffective, severe anaemia is
present, or to preserve vascular access [29]. While it is recog-
nized that some patients may benefit from oral iron therapy,
studies comparing oral with IV iron in ND-CKD populations
have demonstrated that IV iron is superior to oral iron with
regard to replenishing iron stores, and have shown a small but
significant superiority to oral iron with regard to increasing Hb
[26]. These studies, however, have been relatively small and of
short duration, such that the long-term safety and efficacy of
either type of therapy has not been fully elucidated.
The potential benefits of oral iron include convenience and
low cost per dose. However, intestinal absorption of iron is
often poor, particularly in patients with ND-CKD who are at
an increased risk of inflammation with elevated C-reactive
protein (CRP) and hepcidin levels. Additionally, gastrointesti-
nal complications are frequently observed when ferrous salts
such as ferrous sulphate are used, and adherence can therefore
often be poor, an issue compounded by high pill burden [30].
IV iron administration bypasses the problem of poor absorp-
tion in the gastrointestinal tract and can more rapidly and effi-
ciently provide iron for erythropoiesis and replenishment of
iron stores.
Other important issues that remain unresolved are the
optimal dose of IV iron and the appropriate target levels for
serum ferritin and TSAT when administering iron therapy.
No randomized trial has systematically examined the efficacy
and safety of dosing based on specific serum ferritin or TSAT
ranges, so it has not been possible to develop strong evidence-
based guidelines on this issue [16, 31]. In one prospective
cohort study of 228 unselected patients receiving haemodialy-
sis treated with ESA therapy and IV iron sucrose which used
protocol-stipulated dose adjustments according to both Hb
concentration, percentage hypochromic red cells (< 2%) and
serum ferritin level (100–500 µg/L), a close inverse correlation
was observed between serum ferritin level and the mean dose of
ESA that was required [32]. Consistent with this, Descombes
et al. observed in a series of 25 patients receiving haemodialysis
that adjusting IV iron dose to target a serum ferritin level of
200–600 µg/L achieved ∼30% reduction in ESA dose while
maintaining the same mean Hb level [33]. It may therefore be
hypothesized that targeting higher serum ferritin levels could
permit delayed or reduced ESA dosing in the ND-CKD popu-
lation. Hence, the Ferinject® assessment in patients with iron
deficiency anaemia and non-dialysis dependent chronic kidney
disease (FIND-CKD) study assessed whether targeting higher
ferritin levels with IV iron is more effective than oral iron or,
indeed, targeting lower ferritin levels with IV iron.
CURRENT CLINICAL QUESTIONS
Clinicians managing patients with ND-CKD and iron
deficiency, with or without anaemia, currently lack of rigorous
data to inform their decision-making regarding the timing and
route of administration for iron therapy, the optimal serum
ferritin and/or TSAT targets, and when to use ESA therapy.
The FIND-CKD study was undertaken to address these
important clinical questions and to assist the clinician in
managing anaemia in their patients with ND-CKD. The study
employed a rigorous study design that compared IV iron
therapy targeting pre-defined serum ferritin levels versus oral
iron therapy, in terms of preventing or delaying the use of
other anaemia management therapies (e.g. ESA therapy, other
iron therapy or blood transfusions) and a number of other
clinically pertinent secondary end points. The study was also
designed to address the question of whether targeting a higher
or lower serum ferritin level with IV iron is more effective
than oral iron.
THE FIND-CKD STUDY DESIGN
Overview
FIND-CKD was a 56-week, open-label, multicentre, prospec-
tive, randomized, three-arm study (ClinicalTrials.gov identifier:
NCT00994318) (Figure 1). The primary objective of the study
was to evaluate the long-term efficacy of IV FCM (using targeted
serum ferritin levels to determine dosing) or oral iron to delay
and/or reduce use of ESA therapy or other anaemia manage-
ment options in patients with ND-CKD and iron deficiency
anaemia. FIND-CKD was the first randomized trial to compare
IV versus oral iron using two different IV iron dosing schemes
based on a target range for serum ferritin of 400–600 and 100–
200 µg/L—‘high ferritin’ and ‘low ferritin’ FCM dosing groups,
respectively. The schedule of study procedures is summarized in
Supplementary Material, Appendix S1.
The FIND-CKD study employed a treatment algorithm that
reflects the latest international guidance on anaemia manage-
ment in CKD from KDIGO [16], which recommends that iron
deficiency should be treated before ESA therapy is initiated. The
protocol also employed a cautious approach to the introduction
of ESA, i.e. ESA therapy was only considered in cases when the
Hb level falls <10.0 g/dL, reflecting changes in the prescribing
information for ESA therapy from the U.S. Food and Drug
Administration (FDA) [34].
FIND-CKD was the longest duration randomized controlled
trial of IV iron therapy to be performed to date in patients with
ND-CKD. Patients were recruited into the 56-week study at 193
sites in 20 countries: Australia, Austria, Belgium, Czech Repub-
lic, Denmark, France, Germany, Greece, Italy, the Netherlands,
Norway, Poland, Portugal, Romania, Spain, Sweden, Switzer-
land, Turkey, UK and the USA. The study was conducted ac-
cording to the principles of the Declaration of Helsinki and the
ICH Guidelines for Good Clinical Practice. All patients pro-
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Selection of study population
The study population was comprised of patients with ND-
CKD who had one or more Hb level between 9 and 11 g/dL, and
any single serum ferritin level <100 (or <200 µg/L with TSAT
<20%), within the 4 weeks prior to randomization (Table 2).
These criteria were chosen based on the European Renal Best
Practice guidelines at the time of study initiation, which rec-
ommended targeting an Hb concentration of 11–12 g/dL with a
lower limit of 100 µg/L for serum ferritin and 20% for TSAT
[36]. The lower Hb limit of 9 g/dL was selected to exclude
patients with severe anaemia, who would be more likely to
require blood transfusion within the first 8 weeks of the study
and who, if randomized to oral iron, may not have received ap-
propriate iron management [16]. While serum ferritin <100 µg/L
indicates the presence of absolute iron deficiency in CKD,
functional iron deficiency may be present despite normal
serum ferritin levels, i.e. the patient can be regarded as iron-
deficient even when serum ferritin exceeds 100 µg/L if
inadequate iron is available for erythropoiesis. Therefore, an
inclusion criterion of serum ferritin <200 µg/L with TSAT
<20% [37] was also used. Additional entry criteria were also
applied to ensure that patients did not have rapidly deteriorat-
ing renal function, to minimize the risk that a patient would
progress to end-stage renal failure during the 12-month study
(Table 2). All patients were required to be ‘ESA naïve’, defined
as no exposure to ESA therapy in the 4 months prior to ran-
domization. Oral iron therapy (>100 mg iron/day) was to be
discontinued at least 1 week prior to randomization.
Key exclusion criteria are summarized in Table 2.
Randomization
In total, 626 patients were randomized in a 1:1:2 randomiz-
ation ratio (high ferritin FCM group: low ferritin FCM group:
oral iron group). This ratio was selected to ensure a 1:1 ran-
domization ratio for FCM therapy versus oral iron and a 1:1
comparison between the high ferritin and low ferritin FCM
groups, with balanced recruitment to FCM or oral iron
therapy overall.
Intervention
The FCM doses in the high ferritin and low ferritin groups
were adjusted to a target serum ferritin level in the range 400–
600 and 100–200 µg/L, respectively. An initial dose of 1000 mg
iron in the high ferritin group (500 mg iron on Days 0 and 7 in
patients weighing ≤66 kg) and 200 mg iron in the low ferritin
group was administered on Day 0 if the serum ferritin level was
<100 µg/L. During Weeks 4–48, FCM was administered every 4
weeks if the serum ferritin level was <400 µg/L in the high ferri-
tin group or <100 µg/L in the low ferritin group and if TSAT
was <40% (Figure 2). For subjects with a TSAT >35% from a
prior assessment (completed >10 days prior to the planned day
of FCM administration), dosing was withheld until the TSAT
level was confirmed to be <40%.
Oral iron therapy consisted of commercially available ferrous
sulphate, administered at a dose of 200 mg iron/day to Week
52. Dosing was suspended if the serum ferritin was 200 µg/L or
higher, and was resumed if the serum ferritin level fell below
100 µg/L.
Initiation of other anaemia management
During the first 8 weeks after the start of randomized therapy,
subjects were not to receive ESA therapy, red cell transfusion or
any other treatment to manage the Hb level unless there was an
absolute requirement (e.g. severe or serious adverse reaction to
randomized treatment, unable to continue assigned medication
or rapid Hb drop requiring ESA therapy or transfusion). After
this initial 8-week period, ESA or other therapies could be
F IGURE 1 : FIND-CKD study design. ESA-naïve was defined no exposure to ESA therapy in the four months prior to randomisation. ESA,
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initiated as per local practice if the Hb level decreased to <10
g/dL, and could include any combination of ESA, iron therapy
(oral, IV or intramuscular), blood transfusion or other thera-
pies to achieve and maintain the Hb level within the applicable
guideline range. ESA therapy was not permitted in subjects
with Hb level ≥10 g/dL. An alternative form of iron therapy
was only to be initiated in subjects with Hb level >10 g/dL
when the subject could not comply or tolerate the randomized
treatment arm.
Study end points
The primary end point of the study was time to initiation of
other anaemia management, such as ESA therapy or transfusion
or an Hb trigger (two consecutive Hb values <10 g/dL and
without an Hb increase ≥0.5 g/dL during Weeks 8–52). Intro-
duction of an alternative iron product, or a change in the proto-
col-specified dosing schedule or total iron dose to address a lack
of efficacy or a treatment-related adverse event, was also re-
garded as meeting the primary end point. Secondary end points
are summarized in Table 3.
Statistical analysis
The primary end point, time to the initiation of other
anaemia management or Hb trigger, is being analysed in all
intent-to-treat (ITT) subjects based on Kaplan–Meier survival
analyses, using the log rank test to compare treatment arms.
Three primary comparisons will be made using a hierarchical
step-down procedure to preserve the overall α level of 0.05, in the
following order: (i) high ferritin FCM versus oral iron, (ii) high
ferritin FCM versus low ferritin FCM and (iii) low ferritin FCM
versus oral iron. The sample size calculation (Supplementary
Material, Appendix S2) indicated that 360 subjects were required
to provide 90% power to detect a difference in the primary end
point between the high ferritin FCM group and the oral iron
group, which is considered to be the primary comparison.
For continuous secondary end points, analysis of covariance
models will be used, implementing repeated measures pro-
cedure, and including treatment group, visit, pooled country,
baseline Hb and/or baseline ferritin as covariates. For categori-
cal end points, survival analyses and logistic regressions will be
performed, and odds ratios will be used to compare treatment
Table 2. Key inclusion and exclusion criteria
Key inclusion criteria Key exclusion criteria
≥18 years History of acquired iron overload
ND-CKD Known hypersensitivity reaction to any component of ferrous sulphate or FCM (subjects with
hypersensitivity to other forms of iron were permitted to participate)
eGFR ≤60 mL/min/1.73 m2 (MDRD [35]) Documented history of discontinuing oral iron products due to significant gastrointestinal
distress
eGFR loss ≤12 mL/min/1.73 m2/yeara and predicted TSAT >40% at screening
eGFR ≥15 mL/min/1.73 m2 in 12 monthsb Known active infection, CRP >20 mg/L
Any single Hb level between 9 and 11 g/dL within 4 weeks
of randomization
Clinically significant overt bleeding
Any single serum ferritin <100, or <200 µg/L with TSAT
<20%, within 4 weeks of randomization
Active malignancyc
No exposure to ESA therapy in last 4 months prior to
randomization
History of chronic alcohol abuse (alcohol consumption >40 g/day).
Chronic liver disease and/or screening alanine transaminase or aspartate transaminase greater
than three times the upper limit of the normal range
Active HIV infection or AIDS syndrome, or active hepatitis B or C virus infectiond
Anaemia due to reasons other than iron deficiency (e.g. haemoglobinopathy). Subjects with
treated vitamin B12 or folic acid deficiency were permitted
IV iron and/or blood transfusion in previous 30 days prior to screening or during screening
period
Oral iron therapy at doses >100 mg/day dosing were to be discontinued at least 1 week prior to
randomization
Receipt of oral iron therapy (>100 mg/day) for >3 monthse
Immunosuppressive therapy that may lead to anaemia
Currently requiring renal dialysis or anticipated dialysis or transplantation during the study
Anticipated need for surgery that may result in significant bleeding (>100 mL)
Currently suffering from chronic heart failure New York Heart Association Class IV
Poorly controlled hypertension (>160 mmHg systolic pressure or >100 mmHg diastolic
pressure)
Acute coronary syndrome or stroke within the 3 months prior to screening
Body weight <35 kg
eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; FCM, ferric carboxymaltose; MDRD, modification of diet in renal disease; ND-CKD, non-dialysis
dependent chronic kidney disease; TSAT, transferrin saturation.
aBased on ≥2 appropriately representative values over ≥4 weeks prior to randomization (ideally three values over ≥3 months).
bEstimated based on previous eGFR values. If ≥3 eGFR values are available in the two years prior to randomization, the predicted eGFR at 12 months was calculated using three
appropriately representative values.
cClinical evidence of current malignancy or not in stable remission for at least 5 years since completion of last treatment with exception of basal cell or squamous cell carcinoma of the
skin, and cervical intraepithelial neoplasia.
dKnown positive serology to HIV antibodies or hepatitis B antigen, hepatitis C antibody with clinical signs of active hepatitis.
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groups. The significance level will be set at α = 0.05 and no ad-
justment will be made for testing multiple secondary outcomes.
The ITT population will be comprised of all subjects who
received at least one dose of randomized treatment and attended
at least one post-baseline visit. The safety population will include
all subjects who received at least one dose of randomized treat-
ment. All statistical analyses will be performed using SAS
Version 9.0 or later (SAS Institute Inc. SAS/STAT, Cary, NC).
CLINICAL RELEVANCE OF THE FIND-CKD
RESULTS
An evidence-based approach to the use of iron therapy for the
treatment of iron deficiency anaemia in patients with ND-
CKD has been hampered by a lack of randomized, controlled
trials of sufficient size and duration. Additionally, the majority
of trials have been performed in ND-CKD patients receiving
ESA therapy and have used Hb response as their primary end
point, and the limitations of this approach have become clear
in recent years. A clinical trial such as FIND-CKD is therefore
long overdue. The results of FIND-CKD are also likely to
receive particular attention in light of safety concerns related
to ESA therapy, particularly at high doses [34, 38, 39], and the
2012 KDIGO Anemia Guideline [16].
Unlike in haemodialysis patients where IV iron is univer-
sally recommended, there is currently no international con-
sensus regarding which route of administration of iron
therapy is more appropriate for the treatment of iron
deficiency anaemia in patients with ND-CKD. The choice of
F IGURE 2 : Study treatment. FCM, ferric carboxymaltose.
Table 3. FIND-CKD study end points and safety evaluations
Efficacy end points Safety evaluations
Primary end point Clinical laboratory tests (haematology, serum chemistry,
urinalysis, hormone levels)
Time to initiation of other anaemia management (e.g. ESA or transfusion) Concomitant medication
Secondary end points Adverse events, including severity and relationship to study
medication
Cumulative ESA dose Adverse events and serious adverse events leading to study
withdrawal
Requirement for transfusion Physical examination (unusual findings)
Cumulative iron dose and number of iron administrations Vital signs (blood pressure, temperature, heart rate and body
weight)
Increase of Hb ≥1 g/dL prior to any other anaemia management
(e.g. ESA or transfusion)
Abnormal features on electrocardiogram
Change from baseline to end of study for haematological and iron parameters
Change from baseline to end of study for eGFR (MDRD formula)
Requirement for dialysis
Change in health-related quality of life from baseline to end of study (SF-36)
Health resource utilization over the study period (direct, indirect and total costs from
payer’s and societal perspective)
Cost effectiveness of treatment options using relevant effectiveness parameters
Percentage of subjects discontinuing the study drug due to intolerance
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route of administration therefore often varies from country to
country and from centre to centre, and indeed among individ-
ual nephrologists within the same centre. FIND-CKD will
provide a robust comparison of the effectiveness and safety of
the two routes of administration and help inform clinical prac-
tice in patients with ND-CKD not receiving ESA therapy. In
addition, the study will examine whether the route of adminis-
tration and dosing protocol has benefits beyond achieving
certain laboratory targets, such as a significant impact on
quality of life.
FIND-CKD will also evaluate the potential for IV iron
therapy targeting pre-defined serum ferritin levels, and for
oral iron, to delay, reduce or avoid ESA administration as
well as other anaemia treatment options such as other iron
therapy or blood transfusions. Avoiding or decreasing blood
transfusions would be welcomed given the recent increase in
blood transfusions that has occurred since the publication of
CREATE [12], CHOIR [13, 14] and TREAT [15], coupled
with the FDA-mandated change in the ESA label, as well as
the risk of transfusion-induced sensitization to human leuko-
cyte antigens with adverse effects on waiting time for trans-
plantation and immunological status following transplant
[40, 41].
The study protocol specified that ESA therapy should not
be initiated until the Hb level was <10 g/dL, which is consist-
ent with the latest guidance from KDIGO [16] and the FDA
[34]. Using this contemporary protocol, particular attention
will be paid to the proportion of subjects requiring ESA
therapy, and whether the IV route of administration utilizing a
high ferritin or low ferritin target compared with the oral
route confers any additional benefit in terms of a reduction in
the requirement for ESA therapy.
Data on the progression of renal function [eGFR (modifi-
cation of diet in renal disease formula)] will also be of particu-
lar interest since there are several studies with conflicting
results regarding the impact of iron therapy on renal function.
Some small clinical studies have suggested that IV iron
therapy may adversely affect renal tubular function and in-
crease proteinuria [42–44]. The effect of IV iron on renal func-
tion in FIND-CKD (a secondary end point) will therefore be
of great interest. Furthermore, FIND-CKD will allow a direct
comparison of the safety profile of IV versus oral iron therapy,
although it should be noted that the trial was powered for the
primary efficacy end point, not for a safety end point.
Finally, the study will evaluate the cost effectiveness of each
treatment arm. A key aspect of anaemia management is the
cost of ESA therapy, which represents the largest drug expen-
diture for ND-CKD patients [45]. In other therapeutic areas, it
has been proposed that the use of FCM is cost saving due
largely to reduced requirements for ESA [46]. Results of the
health economic assessment will help to determine the cost
impact of FCM in the setting of ND-CKD and, specifically, if
IV iron dosing according to different serum ferritin targets is
cost saving compared with oral iron.
Answers to these questions from the FIND-CKD trial are
awaited with interest by the nephrology community. Recruit-
ment to the study has been completed, and the first results
from the study are expected in late 2013.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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